TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).
Quantum BioPharma is at the center of a significant legal battle, alleging stock market manipulation by two major Canadian banks, CIBC and RBC, through a practice known as stock spoofing. This claim is part of a $700 million lawsuit, which has gained public attention through a three-part investigative series by CTV News’ W5 program. The company aims to highlight the detrimental effects of such illegal activities on its operations and stakeholders, while also promoting its groundbreaking drug, Lucid-MS, designed to combat multiple sclerosis.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which has shown promise in preclinical models for treating multiple sclerosis. Quantum BioPharma also holds strategic investments and retains a significant stake in Unbuzzd Wellness Inc., which markets the unbuzzd™ product.
Average Trading Volume: 3,192
Technical Sentiment Signal: Sell
Current Market Cap: C$61.95M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.